KalVista Pharmaceuticals, Inc.

KALV

US4834971032

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 07:49:13 18/06/2024 pm IST			5-day change	1st Jan Change
11.73 ^USD	-0.76%		-3.78%	-4.33%

12:58pm	KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks	DJ
12:30pm	KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema	CI

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2023

July 07, 2023

KalVista Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended April 30, 2023. For the fourth quarter, the company reported net loss was USD 26.31 million compared to USD 24.11 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 0.98 a year ago.

Latest news about KalVista Pharmaceuticals, Inc.

KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks	04:28pm	DJ
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema	04:00pm	CI
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06/06	CI
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	03/06	CI
Sector Update: Health Care Stocks Higher Late Afternoon	01/06	MT
Sector Update: Health Care	01/06	MT
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	31/05	MT
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	31/05	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	22/05	MT
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22/04	CI
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	12/03	CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03	CI
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	08/03	MT
KalVista Pharmaceuticals, Inc. Announces Board Changes	07/03	CI
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	07/03	CI
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency	20/02	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing	17/02	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing	17/02	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing	17/02	MT
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	16/02	CI

Chart KalVista Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Sector

Pharmaceuticals

Calendar

04/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.82 USD

Average target price

29.8 USD

Spread / Average Target

+152.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KALVISTA PHARMACEUTICALS, INC.	-4.33%	499M
CSL LIMITED	+2.52%	92.1B
SAMSUNG BIOLOGICS CO.,LTD.	-3.16%	37.92B
BIOGEN INC.	-12.22%	32.97B
UCB	+75.22%	27.92B
BIOMARIN PHARMACEUTICAL INC.	-11.52%	16.14B
INCYTE CORPORATION	+0.73%	14.1B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.18%	11.66B
ALTEOGEN INC.	+171.57%	10.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.45%	9.99B

Biopharmaceuticals